AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 17, 2024
(SimpleImages/Getty Images) A high-cholesterol animal product eaten by billions of people worldwide is not as bad for your health as it’s often cracked up to be. It might even be good for you.
JAMA Internal Medicine
NOVEMBER 17, 2024
This systematic review and meta-analysis evaluates the association of sodium correction rates with mortality among hospitalized adults with severe hyponatremia.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 17, 2024
The Indian healthcare industry has made significant strides in improving the accessibility and effectiveness of epilepsy treatments in recent years. With the advent of new drugs, advanced surgical options, better diagnostic tools and increased awareness, epilepsy management has seen a positive transformation.
JAMA Internal Medicine
NOVEMBER 17, 2024
This cohort study examines the association of treatment with metformin and add-on antidiabetic medications with asthma attacks.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
FDA Law Blog
NOVEMBER 17, 2024
By JP Ellison — The word unprecedented has been used a lot in the past two weeks. Perhaps appropriately. Below is some precedent that’s been on this blogger’s mind recently and that may be relevant in the coming days, weeks, and months: Tummino v. Hamburg. Why? The HHS Secretary intervened in an FDA approval decision. The court ruled the agency’s action was arbitrary and capricious and entered a mandatory injunction ordering FDA to make the drug available.
JAMA Internal Medicine
NOVEMBER 17, 2024
This diagnostic study compares the specificity and sensitivity of comercial fecal immunochemical tests with a multitarget stool DNA test.
Expert insights. Personalized for you.
246 
Let's personalize your content